Dermatologic and Ophthalmic Drugs Advisory Committee Meeting

The US FDA has scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee Meeting for Monday, March 9, 2015.

During the morning session the committee will discuss new drug application (NDA) 206333, deoxycholic acid injection, a cytolytic drug, submitted by Kythera Biopharmaceuticals, proposed for the improvement in the appearance of moderate-to-severe convexity or fullness associated with submental fat in adults.

During the afternoon session, the committee will discuss pediatric development of systemic products for the treatment of atopic dermatitis with inadequate response to topical prescription therapy.